Antitrust and Health Care

Sen. Richard Blumenthal urged the Federal Trade Commission to disclose the results of its investigation into the U.S. for‑profit dialysis industry and to pursue 'robust' enforcement against Fresenius and DaVita if warranted. The senator told CBS News the FTC has examined whether the two firms’ dominant market share has harmed care quality, but findings have not been made public; he cited concerns about anticompetitive conduct in a sector serving about 500,000 Americans.